Lexaria Bioscience Chairman and CEO Chris Bunka on Disrupting an Industry, DehydraTECH™, and The Art of Being a CEO

We have Lexaria Bioscience Chairman and CEO Chris Bunka stopping by for a fascinating discussion on disruption, the art of being a CEO, and their innovative technology DehydraTECH™. DehydraTECH™ improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs. Chris is a published author and was previously a serial entrepreneur for over three decades. In today's episode, you'll hear: Chris's origin story and what makes him tick The art of being a CEO The thought process behind pivoting Lexaria (and how you can think about pivoting) How Lexaria became what it is today Why you must have your ethics and values in order What is DehydraTECH™ The many potential benefits of DehydraTECH™ The process to get listed on NASDAQ and some things to expect How Chris goes about adding team members (and the number one thing he looks for) What's on the horizon for Lexaria Some of the significant health issues Lexaria is attacking Chris's wellness habits And much more Connect with Chris: Website: https://www.lexariabioscience.com/  Investment platforms: Type LEXX Connect with Julian: Superhuman Optimization & Enhancement Program: https://theartoffitnessandlife.com/us/ Connect with me on Twitter: https://twitter.com/thejulianhayes Connect with me on LinkedIn: https://www.linkedin.com/in/julianhayes